AGORACOM News Flash

AGORACOM Wire - Wednesday February 15th, 2012

Breaking News ....

Lomiko (LMR: TSX-V) to Complete 43-101 Report on Previous Drilling at the Quatre Milles Graphite Property *CLIENT* Read More

Top Sector Stories ....

Strike Graphite Corp. (TSXV:SRK) Acquires Wagon Graphite Project in Quebec in Vicinity of Timcal's Lac des Iles Graphite Mine *CLIENT* Read More | Profile

Strike Graphite goes "Beyond the Press Release"

McLaren Resources (CNSX:MCL) Drills 7.0 Grams Gold Over 7.4 Metres at the TimGinn Property Located Adjacent to the Hollinger Mine *CLIENT* Read More | Watch Beyond the Press Release

DONNER METALS INTERVIEW: David Patterson Discusses the Bracemac-McLeod Mine Development Beyond the Press Release

AGORACOM Launches GraphiteStocksBlog.com

We're proud to announce the launch of GraphiteStocksBlog.com a website dedicated to the needs of investors and companies in the fast growing Graphite industry.

INAUGURAL GRAPHITE SPONSORS

Message: Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure

AGORACOM

Rank: [?]

President

Points: [?]

11204

Rating: [?]

Votes: 30 Score: 4.0

Currently 4.0/5 Stars.

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.

Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure

posted on Apr 08, 08 05:01AM

Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure

MONTREAL, Apr 8, 2008 -- Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization, will hold its Annual General and Special Meeting of Shareholders on:

Mr. Joseph Galli, Chairman & CEO of Haemacure, will report on Haemacure's projects, recent developments and future outlook. Mr. Galli will also present an overview of the current clinical programs for Haemacure's proprietary fibrin sealant and hemostatic agent product candidates, construction of the Company's new manufacturing facility and growth potential.

Live Webcast

For those who are unable to attend in person, Haemacure will simultaneously host a live webcast with slides of Mr. Galli's presentation at http://events.snwebcastcenter.com/haemacure/20080409/

About Haemacure Corporation

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical haemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a human-derived fibrin sealant planned to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant, now in preclinical stage. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical haemostats, wound management, drug delivery, regenerative medicine, adhesion prevention and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these specialty proteins and enzymes through partnerships with pharmaceutical and biotechnology companies.